Literature DB >> 32279065

The Necessity of Clinical Rh Phenotypic Serological Detection and Homotypic Infusion in Patients with Repeated Blood Transfusion.

Yan Liu1, Yan Lv1, Dandan Xu1, Jianping Cao1, Mengqing Wang1, Jue Xie1.   

Abstract

BACKGROUND This study analyzed the distribution of Rh serological phenotype in people living in Hangzhou, China, and assessed the necessity of its routine clinical detection and homotypic infusion. MATERIAL AND METHODS Blood donors and patients who might need blood transfusion were enrolled into the study, and ABO and 5 major Rh serological antigens (C, c, D, E, and e) were routinely detected. The consistent ABO and Rh serological phenotype blood was transfused between the blood donors and recipients. Irregular antibodies were screened and identified in patients before the blood transfusion. Then, the transfusion adverse effects were monitored and compared with the previous data in the hospital. RESULTS The phenotypic frequencies of Rh blood groups were D>C>E>c>e. The CCDee was the most common phenotype and CcdEe was the least common. The detection rate of unexpected antibodies gradually increased, while the unexpected antibodies slowly decreased in the Rh system. There was a correlation between the isotypic infusion of 5 Rh antigens and the detection rate of antibodies in the Rh system (R=0.845). The adverse effects of blood transfusion declined from 19.95% in 2011 with just homotypic ABO infusion to 3.098% in 2019 with the transfusion of homotypic ABO and the 5 major Rh serological antigens. CONCLUSIONS The consistency of the transfusion with ABO and 5 significant Rh serological antigens could prevent and decrease the high frequency production of isoantibodies, which is of vital importance in reducing the incidence rate of adverse effects in patients receiving transfusions.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32279065      PMCID: PMC7171429          DOI: 10.12659/MSM.921058

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


Background

In 1939, Levine and Stetson discovered the human Rh blood group system, and their study has proven that this system is one of the most critical blood group systems next to the ABO system in clinical importance [1,2]. After 2 of the Rh gene cDNAs were cloned in 1990 [2,3], the study of the genetic structure of the Rh blood group system rapidly progressed. As one of the most polymorphic systems of the human blood, the Rh blood group system consists of more than 50 antigens [4,5]. However, only 5 antigens are particularly important in clinical practice, and the antigenicity from strong to weak is as follows: D>E>C>c>e [5,6]. If the Rh antigen-antibody system does not match between the blood donor and the receptor, this might cause a hemolytic transfusion reaction, newborns hemolytic disease (HDN), and autoimmune hemolytic anemia [7,8]. At present, the essential antigens D are commonly detected in every hospital of China and in the world, but only a few have detected the other 4 significant antigens, which might be the most crucial cause of immunoreaction. Our department started to detect the Rh serological phenotype in patients who might need 2 or more blood transfusions, developed the component blood infusion of the same ABO and 5 major antigens of Rh phenotypes since 2013, and generalized the detection to all patients who might need blood transfusion since 2015. The results revealed that the rate from a high level was D, e, C, c, and E, which was in accordance with the reports of previous studies in other populations [9]. After the component blood infusion of consistent ABO and the 5 major Rh antigen types, the adverse effects of blood transfusion in our hospital decreased year by year, from 19.95% in 2012 to 3.098% in 2019, and considerably lowered the occurrence rate. Furthermore, the detection rate of unexpected antibodies gradually increased from 0.18% in 2014 to 0.56% in 2019, while the detection rate of unexpected antibodies slowly decreased in the Rh system in antibody-positive patients, from 72.41% in 2014 to 39.76% in 2019. All these results prove the great importance of Rh homotypic infusion in clinical practice.

Material and Methods

Samples

Approximately 77 180 donor blood samples were supplied by the Blood Center from 2011 to June 2019, and donors who donated 2 times or more were counted as 1 donation using the Blood Center ID numbers. Patients who might need a blood transfusion and applied for it were enrolled in the study. We enrolled 90 891 patients from 2011 to June 2019 in the present study. The total number of samples was 168 071. Adverse effects of patients who received blood transfusions were analyzed in this period at the hospital.

Instruments and reagents

For the indirect anti-globulin assay, micro-column gel cards were purchased from Diana Company. The Rh blood group system appraisal instruments and reagents were obtained from Changchun Company. Spectrum cells (a set of 16) were obtained from Shanghai Blood Biological Medicine Company. Other instruments included the incubation (Diana Company) and centrifugation (BASO Company) process.

Methods

The Rh serological phenotypes of the main 5 antigens in all donors and receptors were detected according to manufacturer’s protocols. The irregular antibody specificity of positive samples with the 1 ball micro-column gel method was further identified using the brine and people indirect anti-globulin methods. Patients who received at least 2 blood transfusions were regarded as the same subject using their unique hospital ID number when analyzing the infusion adverse reactions. The same donors and receptors were taken once when analyzing the Rh serological phenotype with the Blood Center ID number. All results were independently checked by 2 staff.

Statistical analysis

All data are presented as mean±standard deviation (SD), and Student’s unpaired or paired t-test was performed, as appropriate, to compare differences between groups. The Mann-Whitney U-test was performed to compare the non-parametric data between the 2 study groups. A P-value <0.05 was considered statistically significant. The data were analyzed using GraphPad Prism 5 software (Graph Pad Software, Inc., San Diego, CA, USA).

Results

The distribution of Rh phenotypes in subjects

The blood in our hospital was routinely donated by the Blood Center of Zhejiang Province, and this is the only department entitled to provide blood for the hospital. From January 2011 to June 2019, a total of 77 180 blood products were sent to the hospital. There were 90 891 inpatients who might need transfusions. Repetitions were eliminated using the Blood Center ID numbers on the blood bags for donors and the hospital ID number for inpatients. All 168 071 subjects were detected for both the ABO and 5 major Rh serological antigens. Among these subjects, a total of 15 phenotypes were detected. Among these, CCDee was the highest in frequency (44.944%), followed by CcDEe (34.014%), CcDee (8.679%), ccDEE (7.123%), and ccDEe (3.338%). The detailed information is summarized in Table 1. The serological antigen “D” negative was written as “d”.
Table 1

The serological phenotypes of the 5 major antigens in the Rh blood type of all subjects.

No.Rh phenotypeFrequencyPercentage (%)
1CDe/CDe7554144.944
2CDE/cDe5717034.014
3CDe/cDe145878.679
4cDE/cDE119737.123
5cDE/cDe56103.338
6CDE/CDe13170.784
7cDe/cDe5760.343
8cde/cde5060.301
9CDE/cDE3570.212
10Cde/cde3040.181
11Cde/Cde560.033
12cdE/cde380.023
13CDE/CDE160.010
14CdE/cde180.011
15CdE/Cde20.001

The antigen distribution of the Rh blood group system in donors

For all donors, the ratio of these 4 ABO types was as follows: A 30.530%, B 28.478%, O 32.244%, and AB 8.748%. For patients, the ratio was as follows: A 31.417%, B 25.632%, O 34.563%, and AB 8.32%. These results are consistent with those in previous studies [10,11]. There were almost twice as many male donors as female donors. Type “O” was the most common type in Rh (D) positive and negative phenotypes among males and females. The type, along with the other 4 major Rh antigens, was detected in 77 180 donors. Among these donors, 76 636 (99.295%) donors were RhD, and 544 (0.705%) donors were Rhd. In terms of the type of RhD, the CCDee phenotype was the most common type, while in Rhd, this was ccdee. The results are presented in Table 2.
Table 2

The distribution of the Rh blood group system antigen detection in donors.

RHABO
AABBOOABABTotal
MaleFemaleMaleFemaleMaleFemaleMaleFemale
CCDee7032354765373459745237212082108234912
CcDEe509028854767258657592606135580925857
CcDee1379723123660414666373521896586
ccDEE1188492107851012416012931645567
ccDEe5242374643245622861571022656
CCDEe1084910146130683329564
ccDee572660216330209286
CcDEE321936264720811199
ccdee5941373163362017304
Ccdee25272316423087178
CCdee9526322130
ccdEe1031770019
CcdEe3112031112
CCDEE311112009
CCdEe000001001
Total1551080531434676331683680504331242177180

Antigen detection of the Rh blood group system in patients

For patients, the ratio of the 4 ABO types was almost the same as that of donors, but the percentage for females was much higher than that for donors. Type “O” continued to be the most common type among patients in our hospital. The RhD type, along with other major Rh antigens, was detected in 90 891 patients. Among these patients, 90 511 (99.582%) patients were RhD and 380 (0.418%) patients were Rhd. For the type of RhD, the CCDee type was the major type, while for Rhd, the major type was ccdee, and this was consistent with that of the blood donors. The results are presented in Table 3.
Table 3

The antigen distribution of the Rh blood group system in patients.

RHABO
AABBOOABABTotal
MaleFemaleMaleFemaleMaleFemaleMaleFemale
CCDee7155562257414523795262221931148340629
CcDEe5481433244643657609846071468120631313
CcDee139911341149933154212063622768001
ccDEE119184393772112389613042116406
ccDEe4933904483356034281411162954
CCDEe15494108831481013332753
ccDee51364339624289290
CcDEE28222612352456158
ccdee303822203838610202
Ccdee16241410252467126
CCdee9421531126
ccdEe4132341119
CCDEE201202007
CcdEe101031006
CCdEe100000001
Total1601512540129591033817752136634266335890891

The adverse reaction of transfusion from 2011 to Jun 2019

In China, every hospital must comply with the principles of homotypic ABO and RhD infusion for patients who need routine blood transfusions, which is the same for our hospital since before 2013. The investigators started to detect the 5 major antigens of the Rh serological phenotype in patients who might need blood transfusions at least 2 times or more. Then, the component blood infusion was prepared with the same ABO and Rh serological phenotype since October 2013, and the detection was generalized for all patients who needed blood transfusions since October 2014. The total number of infusions for patients from 2011 to June 2019 was 3108, 3329, 4283, 4585, 4871, 4885, 4092, 4373, and 2444, respectively. The number of adverse effects of blood transfusion was 62, 58, 37, 36, 18, 17, 12, 13, and 8, respectively. The adverse effects of blood transfusion in our hospital have decreased year by year: 19.95%, 17.42%, 8.69%, 7.85%, 3.69%, 3.49%, 3.016%, 3.126%, and 3.098%. This proves the delicate relationship between the homotypic Rh transfusion and the adverse effects of blood transfusion. The results are presented in Figure 1. The study investigated the type of adverse effects involving transfusion of different Rh phenotype, and the results are shown in Supplementary Table 1.
Figure 1

The number of receptors and adverse incidences from 2011 to June 2009: With the increase in the number of receptors year by year, the adverse incidence rate decreased from 19.95% to 3.098% after the same Rh serological phenotype infusion, which remained very stable each year. The “2019.6” refers to the period from January to June 2019.

We also assessed the rates of adverse effects among patients who received homotypic infusion and the patients who did not receive homotypic infusion from 2015 to Jun 2019 (as before October 2014 we did not detect all the patients’ Rh serological phenotype). The results showed that there is a statistically significant difference between the 2 groups (P <0.05) (Supplementary Table 2).

Distribution of the 5 major Rh antigens

In the present study, the distribution of the 4 major Rh antigens in Rh (D) positive and negative subjects was analyzed. Interestingly, the most significant difference was the percentage of C and c: C was much higher than c in RhD, while c was much higher than C in Rhd. There was no EE in Rhd in the present study. Furthermore, the present study analyzed the antigen frequency (AF) of the 5 major Rh antigens (Table 4). It was noteworthy that AF is an extremely important clinical indicator for predicting the common alloantibodies that could be formed in patients after receiving repeated transfusions, thereby contributing to the selection of antigen-negative blood for patients with alloantibodies [12]. This is in accordance with studies on multi-transfused thalassemias and hemodialysis patients published from a center in north India [13,14].
Table 4

The antigen frequency (AF) of other Rh antigens (C, c, E, and e) in Rh (D) positive and negative objects in the study.

Number of objectsC AF (%)c AF (%)E AF (%)e AF (%)
Rh (D) positive (167147)89.13654.00845.73492.614
Rh (D) negative (924)41.12693.7236.280100.000
Total (168071)88.87254.22645.51792.654

The correlation among the 5 major antigens of Rh blood transfusions with different antibodies detection

Since our department started to detect the Rh serological phenotype of patients who might need blood transfusion in 2013, the accordance of Rh infusion was stable after 2015, since Rh 5 major antigens were detected in all patients. The rates of the Rh 5 major antigens, in accordance with the transfusion (accordance of Rh) from 2013 to June 2019, were 67.3%, 73.7%, 90.1%, 89.7%, 90.0%, 92.8%, and 92.3%, respectively. The results of the irregular antibody detection revealed that the positive rate gradually increased (0.15%, 0.18%, 0.16%, 0.26%, 0.38%, 0.54%, and 0.56%, respectively), while the Rh system antibody-positive rate decreased (59.13%, 72.41%, 55.56%, 55.56%, 47.14%, 40.90%, and 39.76%, respectively). In addition, a negative correlation was observed between the accordance of the Rh and positive rate of Rh antibody detection (P=0.0167, r=0.9747). In the further analysis of the Rh system antibody, it was found that the E antibody-positive rate was very high: 59.53%, 58.62%, 48.14%, 42.28%, 41.43%, 32.73%, and 31.89%, respectively. There was also a correction between the accordance of the Rh and the positive rate of E antibody detection (P=0.0833, r=0.9000). All these results are presented in Figures 2 and 3. In the study, we analysis the antibody-positive patients according to the body system, and found that the proportion of circulatory system and digestive system was relatively higher than in the other 6 systems, and the difference was statistically different (p<0.05) (Supplementary Table 3).
Figure 2

The results of the rate of the Rh 5 major antigens accordance transfusion (accordance of Rh) and the irregular antibody detection: The accordance of Rh was stable at above 90% after 2015, but the positive rate of irregular antibody detection increased year by year. The correlation between the accordance of Rh and the positive rate of irregular antibody detection was not statistically significant (P=0.2333, r=0.7000).

Figure 3

The results of the accordance of Rh and Rh antibody detection: The positive rate of the Rh antibody detection decreased after 2015, and the correlation with the accordance of Rh was statistically significant (P=0.0176, r=0.9747). The E antibody of the Rh system was the major antibody. The study results revealed that the correlation with the accordance of Rh was not statistically significant (P=0.0833, r=0.9000).

Discussion

The Rh blood group is generally recognized as the second most crucial system in transfusion medicine after the ABO blood type [1,2]. The present study statistically analyzed the distribution difference of the Rh serological phenotype in the population of Hangzhou, Zhejiang province, to determine the necessity of its clinical routine detection and homotypic infusion. We enrolled 168 071 subjects, and the ABO and 5 major Rh serological antigens were detected. Then, the adverse effects of blood transfusions from 2011 to June 2019 in our hospital were compared. The results reveal that this has a large effect in lowering the adverse effects after the same Rh phenotype infusion. The antigen frequency of RhD-positive subjects in the present study was 99.450%, while the frequencies of the other Rh antigens were C 88.872%, c 54.226%, E 45.517%, and e 92.654%. This was in line with previous studies [9,15]. Although antigen D is the most potent immunogen, the AF of the other 4 antigens in this system remained much higher. This can also stimulate the immune system to produce clinically significant antibodies when receiving an infusion of red cells with Rh D, which are compatible and incompatible for C, c, E, or e antigens. However, this might lead to adverse effects from the blood transfusion [16]. Moreover, the specific antibodies of this system were the most frequent antibodies encountered in the pretransfusion testing, which remains the most important reason for hemolytic disease of newborns (HDN) [17]. In the present study, the most common Rh type was CCDee, both in donors and patients, while CcDEe was in second place. These results agree with previously published studies [9,18]. Since these 2 types could reach up to 79.08% in total, these may be a critical factor for the production of alloantibodies and adverse effects of blood transfusion. A total of 27 patients who had adverse effects after blood transfusion in our hospital before 2013 were contacted, and the blood type of the Rh 5 significant phenotypes was analyzed. Among these 27 patients, 15 were CCDee, 9 were CcDee, and 3 were ccDEE. All these patients were given red blood cells of CcDEe. After the development of the homotypic infusion of the Rh 5 major antigens in our department, a decrease in the incident rate of adverse effects was apparent and obvious (Figure 1). All these results show that there is an excellent relationship between the Rh blood group and incidence of adverse effects when there was an incompatible infusion with C, c, E, or e antigens. In addition, some studies reported that the matching for pure antigens (D, C, E, c, e, K, and possibly Fya, Jka, and Jkb) would be successful in preventing alloimmunization in the vast majority of sickle cell disease (SCD) patients [19]. The investigators considered that the rate of adverse effects is very stable at 3%, which might be due to the probability that antigens K, Fya, Jka, and Jkb are not compatible when transfused. There was a decrease in irregular antibody detection after the accordance of Rh. The accordance of Rh was stable at above 90% after the 2015, but the positive rate of irregular antibody detection increased year by year. These analysis results also show there is a correlation between the accordance of Rh and the positive rate of irregular antibody detection, especially the relationship between the accordance of Rh and the Rh antibody detection. The positive rate of Rh antibody detection decreased after 2015, and the correlation with the accordance of Rh was statistically significant. Also, there is a significant difference (p<0.05) in the antibody-positive patients in 8 body systems. As this type of disease is so diverse, it is hard to say which disease easily produces antibody. All these results show that this work has a great effect on patients. The Duffy antigen is encoded by the FY gene, and the Fya and Fyb antigens are encoded by the FY01 and FY02 alleles [20]. A rearranged RhD allele can encode an altered D antigen, which is the so-called partial D antigen, and an individual homozygous for the rearranged RhD allele or compound heterozygous in trans-silenced RhD allele can produce the anti-D alloantibody [21]. The present study took the partial D antigen as RhD-positive for donors and as RhD-negative for patients. Hence, there is no partial D antigen in the present study.

Limitations of the present study

The major limitation of this study was that only the Rh phenotype and not the Rh genotype of the subjects was tested, but the results are beneficial for clinical work. The other limitation is that there was a higher representation of males in the donors (almost twice the number of females), which is very good for the patients, as the females might have a high antibody rate.

Conclusions

The present study provides guidance in establishing a database of Rh distribution in the population of Hangzhou, Zhejiang province. These results imply that the same Rh phenotype infusion might contribute to the reduction in the incidence rate of adverse effects, and that attention should be focussed not only on the ABO system and RhD phenotype, but also on the other 4 antigens of Rh (C, c, E, and e). The present study can be further extended in the future to include molecular investigations. Finally, merely serological investigations were performed. Molecular probes would be more informative, and should be performed in the future. Adverse events involving transfusion of different Rh phenotype 2015 to Jun 2019. Adverse effects among the patients who received homotypic infusion and the patients who did not receive homotypic infusion from 2015 to Jun 2019. Distribution of antibody-positive patients in the 8 body systems from 2015 to June 2019.
Supplementary Table 1

Adverse events involving transfusion of different Rh phenotype 2015 to Jun 2019.

YearAccordance of RhUnaccordance of Rh
Number of receptorsNumber of transfusionNumber of adverse reactionNumber of transfusionNumber of adverse reaction
2015487143891448290.14
2016488543821350389.74
20174092365611436901
2018437340581231592.81
2019.624442256718892.31
Total206651874157192490.711
Supplementary Table 2

Adverse effects among the patients who received homotypic infusion and the patients who did not receive homotypic infusion from 2015 to Jun 2019.

YearNumber of receptorsAccordance of RhAccordance rate of Rh (%)Discordance of Rh
Number of transfusionsNumber of adverse reactionsRate of adverse reaction (‰)Number of transfusionsNumber of adverse reactionsRate of adverse reaction (‰)
201548714389143.1890.148248.3
201648854382132.9689.750347.95
201740923656102.749043624.59
201843734058122.9692.831513.17
2019.62444225673.192.318815.32
Total2066518741563.0490.71924125.72
Supplementary Table 3

Distribution of antibody-positive patients in the 8 body systems from 2015 to June 2019.

Type of systemAntibody positiveAntibody negativeAntibody positive rate (‰)
Circulatory system73291224.46
Digestive system69280823.98
Motor system39263714.57
Respiratory system33254812.79
Urinary system27235911.32
Genital system1822677.88
Nervous system30241112.29
Endocrine system25240910.27
Total3142035115.19
  19 in total

1.  Alloimmunization and red cell autoimmunization in multitransfused thalassemics of Indian origin.

Authors:  Sangeeta Pahuja; Mukta Pujani; Santosh Kumar Gupta; Jagdish Chandra; Manjula Jain
Journal:  Hematology       Date:  2010-06       Impact factor: 2.269

2.  Blocked D phenomenon, a rare condition with Rh D haemolytic disease of newborn - a case report.

Authors:  P V Sulochana; A Rajesh; J Mathai; S Sathyabhama
Journal:  Int J Lab Hematol       Date:  2008-01-18       Impact factor: 2.877

3.  Rh phenotype, allele and haplotype frequencies among 51,857 blood donors in North India.

Authors:  Raj Makroo; Richa Gupta; Aakanksha Bhatia; Nakamatathil L Rosamma
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

4.  Rh, Kell, Duffy, Kidd and Diego blood group system polymorphism in Brazilian Japanese descendants.

Authors:  Marli Aparecida Luvisuto Rossett Flôres; Jeane Eliete Laguila Visentainer; Gláucia Andréia Soares Guelsin; Adriana de Souza Fracasso; Fabiano Cavalcante de Melo; Margareth Naomi Hashimoto; Ana Maria Sell
Journal:  Transfus Apher Sci       Date:  2013-10-09       Impact factor: 1.764

5.  Maternal red blood cell alloantibodies identified in blood samples obtained from Iranian pregnant women: the first population study in Iran.

Authors:  Ehsan Shahverdi; Mostafa Moghaddam; Fateme Gorzin
Journal:  Transfusion       Date:  2016-11-07       Impact factor: 3.157

6.  Frequencies of red blood cell major blood group antigens and phenotypes in the Chinese Han population from Mainland China.

Authors:  Y Yu; C Ma; X Sun; X Guan; X Zhang; J Saldanha; L Chen; D Wang
Journal:  Int J Immunogenet       Date:  2016-06-19       Impact factor: 1.466

7.  Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.

Authors:  Mohammed Shujauddin Akhil; Balaji Kirushnan; Melvin Martin; Kanakaraj Arumugam; N K Ganesh Prasad; Rajan Ravichandran
Journal:  Nephrology (Carlton)       Date:  2018-05       Impact factor: 2.506

8.  Systematic RH genotyping and variant identification in French donors of African origin.

Authors:  Sandrine Kappler-Gratias; Carine Auxerre; Isabelle Dubeaux; Marylise Beolet; Maryline Ripaux; Pierre-Yves Le Pennec; Bach-Nga Pham
Journal:  Blood Transfus       Date:  2013-06-17       Impact factor: 3.443

9.  Incidence of alloantibody formation after ABO-D or extended matched red blood cell transfusions: a randomized trial (MATCH study).

Authors:  Henk Schonewille; Áine Honohan; Leo M G van der Watering; Francisca Hudig; Peter A Te Boekhorst; Ankie W M M Koopman-van Gemert; Anneke Brand
Journal:  Transfusion       Date:  2015-10-07       Impact factor: 3.157

10.  Genomic analyses of RH alleles to improve transfusion therapy in patients with sickle cell disease.

Authors:  Marion E Reid; Christine Halter Hipsky; Kim Hue-Roye; Carolyn Hoppe
Journal:  Blood Cells Mol Dis       Date:  2013-12-02       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.